Skip to main content

Table 2 Univariate and multivariate analyses for overall survival in the entire cohort (stage III mucinous [n = 81] and serous [n = 162] ovarian carcinoma)

From: Comparison of stage III mucinous and serous ovarian cancer: a case-control study

  Univariate analysis OSa
N of events (%)
p Multivariateanalysis
HR CI 95% p
Age, y
  < 52 36/118 (61.7%) 0.163    
  ≥ 52 47/125 (56.7%)    
Menopausal Status
 Premenopausal 33/96 (56.6%) 0.89    
 Postmenopausal 50/147 (60.5%)    
Ca-125(IU/ml)
  < 310 46/121 (56.2%) 0.089    
  ≥ 310 37/122 (62.2%)    
Grade
 1 33/87 (55.1%) 0.74    
 2–3 50/156 (61.5%)    
Ascites
 Present 62/167 (56.2%) 0.371    
 Absent 21/76 (66%)    
Retroperitoneal LN metastases
 Present 44/112 (39.2%) 0.646    
 Absent 55/131 (41.9%)    
Peritoneal cytology
 Positive 73/198 (56.5%) 0.215    
 Negative 10/45 (71.8%)    
Stage
 IIIA1 6/39 (78.4%) 0.001    
 IIIA2, IIIB, IIIC 77/204 (55.6%)    
Appendiceal Involvement
 Present 41/88 (45%) < 0.001    
 Absent 42/155 (66.9%)    
Omental Involvement
 Present 71/174 (52%) < 0.001    
 Absent 12/69 (77.6%)
Peritoneal Involvement
 Present 67/160 (49.2%) < 0.001 2.39 1.38–4.14 0.002
 Absent 16/83 (76.9%)
Histologic Subtype
 Mucinous 41/81 (44.9%) < 0.001 2.28 1.53–3.40 < 0.001
 Serous 42/162 (66.3%)
  1. a:5-year overall survival rate
  2. Abbreviations: OS Overall Survival, LN Lymph node, HR Hazard ratio, CI Confidence interval, y Year, N number